Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD
Sachin Naik, Shubham Shukla, Niranjan Av, Vinod Kumar, Aravind Sekar, Ritambhra Nada, Manish Rathi, Harbir Singh Kohli, Raja Ramachandran
Abstract
Currently, there are limited options for managing M-Type antiphospholipase A2 receptor antibody-associated membranous nephropathy (MN) with severe chronic kidney disease (CKD) (stage 4 or stage 5).1,2 Obinutuzumab, a humanized type II anti-CD20 receptor antibody, induces more profound and long-lasting B-lymphocyte depletion, culminating in superior clinical response in patients with chronic lymphocytic leukemia.3 In the present manuscript, we report 2 cases of refractory (cyclical cyclophosphamide and corticosteroids, and rituximab) MN with severe CKD managed successfully with obinutuzumab.
Topics & Concepts
MedicineMembranous nephropathyObinutuzumabRefractory (planetary science)Internal medicinePhospholipase A2GlomerulonephritisKidneyBiochemistryLeukemiaEnzymeAstrobiologyPhysicsChemistryChronic lymphocytic leukemiaChronic Lymphocytic Leukemia ResearchRenal Diseases and GlomerulopathiesImmunodeficiency and Autoimmune Disorders